Comment on “Crotalidae Polyvalent Immune Fab and Cost-Effective Management of Hospital Admissions for Snakebites”

Abstract

Get full access to this article

View all access options for this article.

References

Bowden

Christie

Hand

Montgomery

. Crotalidae Polyvalent Immune Fab and cost-effective management of hospital admissions for snakebites. Am Surg. 2022:000313482110545. Published online. DOI: 10.1177/00031348211054566.

Baumgartner

Fishburn

Mullins

. Update on copperhead snakebites in Missouri. Missouri Med. 2019;116(3):201-205.

Ramirez-Cueva

Larsen

Knowlton

, et al. Predictors of FabAV use in copperhead envenomation. Clin Toxicol. 2022:1-6. Published online. DOI: 10.1080/15563650.2021.2018454.

Mullins

Gerardo

Bush

, et al. Adverse events in the efficacy of Crotalidae Polyvalent Immune Fab antivenom vs placebo in recovery from copperhead snakebite trial. South Med J. 2018;111(12):716-720. DOI: 10.14423/SMJ.0000000000000902.

US FDA Center for Biologics Evaluation and Research . Summary basis for approval. https://wayback.archive-it.org/7993/20170722071612/https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM117580.pdf. https://wayback.archive-it.org/7993/20170722071612/https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM117580.pdf. Accessed January 12, 2022